Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-06-07, Stock:NVS, The news for the past five days is as follows:
2021-05-28: NEWS1: Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program.NEWS2: Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies.
2021-06-01: NEWS1: Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis.NEWS2: Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety.
2021-06-02: NEWS1: Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma.NEWS2: Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients.NEWS3: Novartis's Late-stage Study On Cosentyx Hits Primary Endpoint Goal In Juvenile Idiopathic Arthritis.NEWS4: Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients.NEWS5: Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021.
2021-06-03: NEWS1: Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera.NEWS2: Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months.NEWS3: Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study.
2021-06-04: NEWS1: Novartis' Neuroendocrine Tumors Targeted Radiotherapy Takes Small Hit on Clinically Relevant Overall Survival.NEWS2: Novartis (NVS) Announces Data on Radioligand Therapy at ASCO.NEWS3: Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC.NEWS4: Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy.NEWS5: Mesoblast (MESO) Q3 2021 Earnings Call Transcript.

Answer: Decrease